Chemours stock gains after UBS cuts its price target

Published on 10/06/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chemours stock was last at USD 13.89 on October 5, 2026, after UBS cut its target to USD 16. Q2 revenue reached USD 1.591 billion.

CC, US1638511089, Illustration mit AI erstellt.

Chemours stock (ISIN US1638511089) was last at USD 13.89 on the NYSE on October 5, 2026, up 1.31 percent. The immediate trigger was a UBS decision to cut its price target from USD 18 to USD 16 while retaining a Neutral rating, as Markets Insider reported on October 5, 2026.

UBS trims target to USD 16

The new UBS target lies 15.2 percent above the October 5 NYSE price. The cut leaves the target below the previous USD 18 level, sharpening the market debate around Chemours' earnings recovery and balance-sheet demands.

The company had a market capitalization of USD 2.1 billion and traded 2,241,598 shares on October 5, 2026. Its 52-week range was USD 10.44 to USD 28.67, placing the last price USD 14.78 below the yearly high.

Q2 loss masks cash flow gain

In its September 9, 2026 filing and investor presentation, Chemours reported Q2 2026 revenue of USD 1.591 billion, down USD 24 million from USD 1.615 billion in Q2 2025. The GAAP net loss narrowed to USD 274 million from USD 380 million, while adjusted EPS fell to USD 0.42 from USD 0.61.

Adjusted EBITDA reached USD 247 million, compared with USD 260 million a year earlier, and operating cash flow increased to USD 158 million from USD 93 million. Free cash flow rose to USD 114 million from USD 50 million, a 128 percent year-over-year increase, according to Chemours.

Hold consensus meets weak quarter

MarketBeat reported a Hold consensus from 12 analysts, comprising five Buy ratings, six Hold ratings and one Sell rating. The average 12-month target was USD 20.10, which places the target 44.7 percent above the October 5 price.

The same review showed that Q2 adjusted EPS of USD 0.42 missed the USD 0.49 consensus estimate by USD 0.07, while revenue of USD 1.591 billion came in below the USD 1.65 billion estimate. This combination explains why cash generation improved even as the earnings narrative remained under pressure.

TradingView lists October 28, 2026 as the next Chemours earnings date, giving investors the next scheduled checkpoint for revenue, adjusted earnings and cash flow.

Stock remains below yearly high

Chemours stock was last at USD 13.89 on the NYSE on October 5, 2026 at 4:00 p.m. ET, with the session's USD 13.32 low and USD 13.98 high framing the move. The USD 16 UBS target and USD 20.10 consensus target both sit above that level, but the latest quarter still combines a GAAP loss with stronger free cash flow.